Daniel Geffken brings more than 30 years of experience in the life science industry to Elicio Therapeutics. He is the founder and managing director of Danforth Advisors, a financial consulting firm for life science and healthcare companies that has assisted over 300 clients since its founding in 2011. He has served as CFO and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Vigeo Therapeutics, Cabaletta Bio, Inc., Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, he has participated in seven initial public offerings. Over the course of his career, he has raised more than $1 billion in equity and debt securities for life science companies. He holds a bachelor of science degree from The Wharton School at the University of Pennsylvania, and a master’s degree in business administration from Harvard Business School.